SAMSUNG-SEMICONDUCTOR
15.4.2021 10:12:12 CEST | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced digital component solutions, today announced PixCell LED, a new automotive LED module optimized for intelligent headlights, such as adaptive driving beam (ADB) systems. ADB headlamps powered by Samsung’s PixCell LEDs will help improve driver visibility and safety to enhance the overall driving experience at night and in poor weather conditions such as fog or heavy rain.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210415005407/en/
“Much more than a simple automotive lighting source, Samsung’s PixCell LED is based on new lighting technology designed to improve road safety and driving convenience,” said Un Soo Kim, senior vice president of the LED Business Team at Samsung Electronics. “Beginning with PixCell LED, we will introduce tailored lighting solutions well-suited for future automobiles, including electric and autonomous vehicles."
ADB is an advanced driver assistance technology designed to help secure maximum driving visibility. In order to prevent glare to other drivers, ADB automatically adjusts headlight beam patterns when it detects any object near a moving vehicle, thereby preventing any unnecessary glare. Recent developments in future automotive technologies, such as autonomous and connected driving, have been raising the bar for vehicle safety standards and ultimately boosting demand for ADB systems.
Leveraging Samsung’s longstanding expertise in semiconductor technology, the new PixCell LED can monolithically integrate more than 100 ultra-small segments into a single LED chip, while making the light-emitting area significantly smaller.
These LED segments are separated by a silicon wall to prevent optical cross-talk, and in turn, offer superior contrast for much greater driver visibility. Each segment functions like a pixel to meticulously control light distribution, as it distinguishes on and off areas so that the beam from the headlight only illuminates the exact location where it is needed.
With the light-emitting area shrunk to 1/16 of conventional discrete LED modules for ADB systems, the PixCell LED can reduce the headlamp size by 30-50%, allowing greater freedom in designing sleeker and more elegant lamps.
The light distribution and brightness levels of the PixCell LED are designed using automotive lighting software, making them easily adjustable to meet diverse regulations and requirements for automotive lamps around the world. Based on a single standard headlamp design, lamp makers can customize light output to suit varying design needs and enjoy reduced lead time for development, production, supply and time-to-market.
Samsung has begun shipping its PixCell LEDs to lamp manufacturers for use in next-generation electric cars and has already provided enough PixCell LEDs to light more than 300,000 electric vehicles.
Samsung PixCell LED
# of Segments in a Chip |
Light-emitting Surface Size (W x L) |
Contrast Ratio |
Wattage |
100 |
15.4mm x 2.7mm |
300:1 |
Max. 50W |
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210415005407/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 12:00:00 CET | Press release
Improvements in symptoms of pain, stiffness, and range of motion were sustained through two yearsTumor responses remained robust1 and durable2Not intended for U.K.-, U.S.- or Canada-based media Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 11:30:00 CET | Press release
Second limited-edition WHOOP x SR_A collection brings “performance for life” to new WHOOP bands, technical apparel, outerwear, and accessories designed for movement across city and rural environments. WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural wo
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 11:28:00 CET | Press release
Oral-B iO helps you avoid new tooth and gum issues—and if you have existing gum problems, it can resolve them quicker than a manual toothbrush. Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom